Dementia-related Psychosis Market Gearing Up for Outstanding Expansion at a CAGR of 26.2% During the Forecast Period (2026-2036) | DelveInsight

The dementia-related psychosis market is anticipated to increase during the forecast period (2026–2036), owing to the rising burden of dementia, the emergence of novel therapies such as ACP-204 (Remlifanserin) (Acadia Pharmaceuticals), Xanomeline–trospium chloride (COBENFY) (Bristol Myers...